the ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo埃博拉病毒糖蛋白有助于但对体内毒性是不够的.pdfVIP

The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence In Vivo 1,2,3,4 1,3 1,2,3 2 5 Allison Groseth , Andrea Marzi , Thomas Hoenen , Astrid Herwig , Don Gardner , Stephan Becker2, Hideki Ebihara1,3, Heinz Feldmann 1,3,4* 1 Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United ¨ ¨ States of America, 2 Institut fur Virologie, Philipps Universitat Marburg, Marburg, Germany, 3 Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, 4 Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, 5 Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America Abstract Among the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role for the glycoprotein (GP) as a major filovirus pathogenicity factor, but direct evidence for such a role in the context of virus infection has been notably lacking. In order to assess the role of GP in EBOV virulence, we have developed a novel reverse genetics system for REBOV, which we report here. Together with a previously published full-length clone for Zaire ebolavirus (ZEBOV), this provides a un